Boston University
Inhibition of BET bromodomain proteins reverses glucolipotoxicity and improves insulin secretion from clonal pancreatic beta-cells (INS-1)
Abstract
dc:description.abstractBackground. Type 2 diabetes mellitus (T2DM) is driven in by glucolipotoxicity, a combination of chronic hyperglycemia and elevated fatty acid exposure that promotes intracellular lipid accumulation and progressive pancreatic beta-cell dysfunction. JQ1, a pan-bromodomain and extra-terminal (BET) protein inhibitor, has previously been shown to increase fatty acid oxidation and insulin content in pancreatic beta cells, but its ability to counteract glucolipotoxicity specifically has not been established. Objectives. The overall objective of this research was understanding the reverse effect BET protein inhibitor protect INS-1 cells against glucolipotoxicity to improve insulin secretion. This thesis tested whether JQ1 protects INS-1 beta cells against glucolipotoxic lipid accumulation and secretory dysfunction. The three specific aims are: (1) to establish and characterize glucolipotoxic conditions in INS-1 cells that produce quantifiable impairment of insulin secretory function and measurable lipid accumulation; (2) to determine whether JQ1 treatment prevents or reverses glucolipotoxicity-induced lipid droplet and triglyceride accumulation in INS-1 cells; (3) to determine whether JQ1 treatment preserves or restores glucose-stimulated insulin secretion and insulin content under glucolipotoxic conditions; and to relate JQ1's effects on lipid accumulation to its effects on beta-cell functional performance, in order to clarify how JQ inhibition protects against glucolipotoxicity in a model relevant to T2DM. These studies are expected to advance understanding of how JQ1 counteracts glucolipotoxic stress in the pancreatic beta cell and to support its further development as a candidate epigenetic therapy for T2DM. Methods. INS-1 cells were chronically cultured in 11 mM glucose, with or without added oleate and JQ1, and assessed for intracellular lipid droplet content using BODIPY staining, using acute doses 1, 4, 6, 12 mM glucose range, and KCl-stimulated insulin secretion. Additionally, glycerol secretion and assay were assessed using similar method as insulin secretion. Whereas, glycerol oscillation was assessed using column chromatography going from basal to maximal glucose level for glycerol release observation. Results. Chronic culture in 11 mM glucose increased in lipid droplet accumulation compared to 11 mM glucose with JQ1 using imaging and later on measured for insulin content and secretion, an effect amplified by adding additional fatty acid Oleate; co-treatment with JQ1 depleted lipid droplets and triglyceride across all conditions. JQ1 also altered the triggering and amplification pathways of glucose-stimulated secretion, shifting cells away from a blunted, hypersensitized low-glucose profile response toward a more dose-dependent secretory profile, and was associated with greater insulin content. Under KCl stimulation, 11G with JQ1 brings cells back to basal level therefore having a lower KCl response compared to 11G without JQ1. Conclusion. Together, these findings indicate that JQ1-mediated BET inhibition reduces glucolipotoxic lipid accumulation and preserves beta-cell insulin secretion capacity in this model, supporting further investigation of BET inhibition as a candidate epigenetic strategy for protecting beta-cell function in T2DM.
Degree
thesis:*- Name thesis:degree_name
- Master of Science
- Level thesis:degree_level
- masters
- Discipline thesis:degree_discipline
- Nutrition and Metabolism
- Grantor
- Boston University
- Year dc:date.issued
- 2026
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Do, Minh Thu
- Advisors dc:contributor.advisor
-
- Deeney, Jude T.
- Tornheim, Keith
Subjects
dc:subject × 6Rights
- Language dc:language.iso
- en_US
Identifiers
dc:identifier.*- Handle dc:identifier.uri
- https://hdl.handle.net/2144/53536